Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02659059
Title Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb

lung non-small cell carcinoma


Ipilimumab + Nivolumab

Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.